

NOTIFICATION OF UPCOMING EXPIRY OF LISTED OPTIONS

BRISBANE, AUSTRALIA, 5 May 2026: AnteoTech Limited (ASX: ADO) (“AnteoTech” or “the Company”) advises that the attached letter will be sent electronically (via email) to registered holders of listed options (ASX: ADOO) (“Options”) which will expire on 31 May 2026 with an exercise price of \$0.035.

Official quotation of the Options on the ASX will cease at close of trading on 25 May 2026, being four business days before the Expiry Date.

Holders of the Options can exercise all or part of their Options prior to the last business day before the Expiry Date by providing the Company with a completed written Exercise Notice specifying the number of Options being exercised and a payment of funds for the total exercise price for the number of Options being exercised. The Exercise Notice is available by contacting the Company via email at investors@anteotech.com. The last date for receipt of exercise notices and payment is 5:00pm AEST on 29 May 2026.

This announcement has been authorised for release by the Board of AnteoTech Ltd.

— ENDS —

Further Information:

Investors / Company

Merrill Gray

Managing Director / CEO

+61 (07) 3219 0085

investors@anteotech.com

5 May 2026

Sent via Email (where this is recorded with the Company's Share Registry)

Dear Option Holder

RE: NOTICE OF EXPIRY OF LISTED OPTIONS— ADOO

AnteoTech Limited (ASX: ADO) (**AnteoTech** or the **Company**) advises that it currently has on issue 286,628,688 listed options with ASX ticker "**ADOO**", exercisable at \$0.035, which are due to expire on 31 May 2026 ("**Options**").

The Company provides the following information in relation to the Options:

- The number of Options to which this notice applies is **286,628,688**.
- Each Option entitles the holder to receive, on exercise of the Option, one fully paid ordinary share in the Company ("**Share**"). If all the Options were exercised, 286,628,688 Shares would be issued.
- The exercise price of each Option is **\$0.035**.
- The last date for receipt of a valid exercise notice and payment of the exercise price is **5:00pm AEST on Friday, 29 May 2026**. Exercise notices received after this time will not be accepted.
- If payment is not received by 5:00pm AEST on 29 May 2026, the Options will expire on 31 May 2026 with no value and no further entitlement will exist.
- Official quotation of the Options on the ASX will cease at close of trading on **25 May 2026**, being four business days before the Expiry Date.
- The latest available market sale price on ASX before the date of this notice for ADO Shares, being the underlying securities to which the Options relate, was **\$0.012 on 4 May 2026**.
- The highest and lowest market price for Shares during the six months immediately before the date of this notice were as follows:
 - Highest price: **\$0.022** on 8 January 2026.
 - Lowest price: **\$0.010** on 24 March 2026 and 30 April 2026.

If Option holders have any queries in relation to the exercise of their Options, please contact the Company on **+61 (07) 3219 0085** or MUFG Corporate Markets (Share Registry) on **1300 554 474**.

Regards,

Merrill Gray

Managing Director / CEO

About AnteoTech - (ASX: ADO)

AnteoTech is a supplier of advanced material solutions to the battery materials and life sciences markets. We leverage our market leading chemical platform technology to develop and commercialise solutions for our global customer base. From our patented cross linker product Anteo X™ to our next-generation high silicon anode formulations, Ultranode™, and our separator product Anteo S™ our Advanced Battery Technology business is applying its world-leading engineering expertise to address the growing demand for high performance, low cost, sustainable materials and safer batteries within the global battery market. Our Life Sciences business supplies advanced activation materials through our AnteoBind™ suite of products to leading developers and manufacturers of vaccines and diagnostic tests. Our products deliver more sensitive and reproducible results and on incorporation in ‘point of care’ tests, chemiluminescence, enzyme linked immunoassays enable faster, more reliable and accurate test results wherever they are needed.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive our email alert service.

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regard to future events in respect to AnteoTech’ business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.